EIO Biomedical
Postsurgical Adhesion Prevention
Company Overview
Snapshot
Founded in November 2016 by Yair Pilpel, EIO Biomedical operated with 1–10 employees. The company raised $1.5M across two funding rounds from three investors. In June 2017, NGT3 VC announced its investment in EIO Biomedical.
Business overview
EIO Biomedical is a biotechnology company focused on developing a medical device for the prevention of postsurgical adhesions. Its proprietary device and bioprocess convert blood plasma into an enzymatic combination designed to reduce adhesion formation, addressing problems associated with surgical sewing. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics markets with its FuseX system.
Strategic signal
EIO Biomedical ceased operations in January 2023, indicating a significant shift in its corporate trajectory. This cessation of activity suggests that the company's efforts to bring its postsurgical adhesion prevention device to market did not achieve the necessary commercial or clinical milestones to sustain operations, signaling a challenging outcome for its investors and the medical device landscape it aimed to impact.
Log in to access full profile ›Company Intelligence Q&A
- What is EIO Biomedical's primary focus?
- EIO Biomedical develops a medical device for the prevention of postsurgical adhesions, aiming to alleviate issues associated with surgical sewing.
- When was EIO Biomedical founded?
- EIO Biomedical was founded in November 2016.
- Who is a founder of EIO Biomedical?
- Yair Pilpel is a founder of EIO Biomedical.
- What is the status of EIO Biomedical?
- EIO Biomedical is non-active and ceased to operate in January 2023.
- Which investors participated in EIO Biomedical's funding rounds?
- NGT3 and Israel Innovation Authority participated in EIO Biomedical's funding rounds in June 2017 and January 2019.